XML 156 R79.htm IDEA: XBRL DOCUMENT
v3.26.1

List of subsidiaries (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Disclosure of subsidiaries [abstract] |
Disclosure of the principal subsidiaries of the Company | The following list contains the material subsidiaries of the Group at December 31, 2025 and 2024 are as follows:
Name of subsidiaries |  | Place of incorporation/ operation |  | Issued and fully paid share capital |  | Proportion of nominal value of issue capital held by the Company |  | Principal activities
|  |  |  |  |  | 2025 |  | 2024 |  |
|  |  |  |  |  | Directly |  | Indirectly |  | Directly |  | Indirectly |  |
|  |  |  |  |  | % |  | % |  | % |  | % |  |
Prenetics Limited |  | Hong Kong |  | HK$415,276,716 |  | — |  |  | 100 |  |  | — |  |  | 100 |  |  | Genetic and diagnostic health testing
Europa Partners Holdings, LLC (note 33) |  | The United States |  | GBP11.00 |  | — |  |  | 100 |  |  | — |  |  | 100 |  |  | Provision of fulfillment and distribution services of sports nutrition products
IM8 Group Holding Company |  | Cayman Islands |  | $1 |  | 100 |  |  | — |  |  | 100 |  |  | — |  |  | Sales of consumer health products
IM8 (US) LLC |  | The United States |  | n/a |  | 100 |  |  | — |  |  | 100 |  |  | — |  |  | Sales of consumer health products
IM8 Limited |  | Hong Kong |  | HK$1 |  | 100 |  |  | — |  |  | 100 |  |  | — |  |  | Sales of consumer health products
ACT Genomics Holdings Company Limited |  | Cayman Islands |  | $16,713 |  | — |  |  | — |  |  | 73.27 |  |  | — |  |  | Precise cancer genetic testing services
ACT Genomics Co., Ltd. |  | Taiwan |  | TWD455,080,000 |  | — |  |  | — |  |  | — |  |  | 73.21 |  |  | Precise cancer genetic testing - services
ACT Genomics (Hong Kong) Limited |  | Hong Kong |  | HK$775,000 |  | — |  |  | — |  |  | — |  |  | 73.27 |  |  | Precise cancer genetic testing - services
Sanomics Limited |  | Hong Kong |  | HK$500,000 |  | — |  |  | — |  |  | — |  |  | 73.27 |  |  | Precise cancer genetic testing - services
MC Diagnostics Limited |  | United Kingdom |  | GBP1,164 |  | — |  |  | — |  |  | — |  |  | 73.27 |  |  | Sales of medical diagnostics products
The following table summaries the information relating each of the Group's subsidiaries that has material non-controlling interests, before any intra-group eliminations.
| As at October 1, 2025 |  | As at December 31, 2024
ACT Genomics |  |  |
Non-controlling interests percentage | 26.73 | % |  | 26.73 | %
| As at October 1, 2025 |  | As at December 31, 2024
Non-current assets | $ | 44,120 |  |  | $ | 27,549 |
Current assets | 7,380 |  |  | 13,304 |
Non-current liabilities | (3,128) |  |  | (4,297) |
Current liabilities | (5,353) |  |  | (7,797) |
Equity attributable to equity shareholder of the parent Company | 44,187 |  |  | 21,072 |
Equity attributable to non-controlling interests | (1,168) |  |  | 7,687 |
| January 1, 2025 to October 1, 2025 |  | January 1, 2024 to December 31, 2024
Revenue | $ | 12,471 |  |  | $ | 17,653 |
Expenses | (21,240) |  |  | (30,413) |
Loss for the year | $ | (8,769) |  |  | $ | (12,760) |
Loss attributable to equity shareholder of the parent Company | $ | (6,425) |  |  | $ | (9,397) |
Loss attributable to non-controlling interests | (2,344) |  |  | (3,363) |
Loss for the year | $ | (8,769) |  |  | $ | (12,760) |
Other comprehensive income/(expense) attributable to equity shareholder of the parent Company | $ | 184 |  |  | $ | (574) |
Other comprehensive income/(expense) attributable to non-controlling interests | 66 |  |  | (210) |
Other comprehensive income/(expense) for the year | $ | 250 |  |  | $ | (784) |
Total comprehensive expense attributable to equity shareholder of the parent Company | $ | (6,241) |  |  | $ | (9,971) |
Total comprehensive expense attributable to non-controlling interests | (2,278) |  |  | (3,573) |
Total comprehensive expense for the year | $ | (8,519) |  |  | $ | (13,544) |
Net cash (outflow)/inflow from operating activities | $ | (3,536) |  |  | $ | 5,483 |
Net cash outflow from investing activities | (238) |  |  | (318) |
Net cash outflow from financing activities | (961) |  |  | (1,413) |
Net cash (outflow)/inflow | $ | (4,735) |  |  | $ | 3,752 |
Dividends paid to non-controlling interests | $ | — |  |  | $ | — |

X
- Definition The disclosure of interests in subsidiaries. [Refer: Total for all subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph 2 -Subparagraph b -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_2_b_i&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration